Volume 22, Number 6—June 2016
Research
Human Adenovirus Associated with Severe Respiratory Infection, Oregon, USA, 2013–2014
Magdalena Kendall Scott
, Christina Chommanard, Xiaoyan Lu, Dianna Appelgate, LaDonna Grenz, Eileen Schneider, Susan I. Gerber, Dean D. Erdman, and Ann Thomas
, Christina Chommanard, Xiaoyan Lu, Dianna Appelgate, LaDonna Grenz, Eileen Schneider, Susan I. Gerber, Dean D. Erdman, and Ann Thomas
Table 1
Demographic and clinical characteristics for HAdV-positive case-patients, Oregon, October 2013–July 2014*
| Characteristic | Total | HAdVs-B3, -B21 | HAdV-B7 | HAdVs-C1, -2, -5 | Not available† |
|---|---|---|---|---|---|
| Total |
198 (100) |
16 (8.1) |
64 (32.3) |
28 (14.1) |
89 (45.0) |
| Age group, y | |||||
| Children, <18 y | 118 (59.6) | 8 (50.0) | 28 (43.8) | 27 (96.4) | 54 (60.7) |
| <2 | 63 (31.8) | 3 (18.8) | 16 (25.0) | 25 (89.3) | 19 (21.4) |
| 2–5 | 24 (12.1) | 4 (25.0) | 5 (7.8) | 1 (3.6) | 14 (15.7) |
| 6–10 | 20 (10.1) | 0 | 4 (6.3) | 1 (3.6) | 15 (16.9) |
| 11–18 | 11 (5.6) | 1 (6.3) | 3 (4.7) | 0 | 6 (6.7) |
| Adults, >18 y | 80 (40.4) | 8 (50.0) | 36 (56.3) | 1 (3.6) | 35 (39.3) |
| 19–25 | 16 (8.1) | 0 | 6 (9.4) | 0 | 10 (11.2) |
| 26–45 | 19 (9.6) | 2 (12.5) | 10 (15.6) | 0 | 7 (7.9) |
| 46–65 | 35 (17.7) | 6 (37.5) | 18 (28.1) | 1 (3.6) | 10 (11.2) |
| >65 |
10 (5.1) |
0 |
2 (3.1) |
0 |
8 (9.0) |
| Common symptoms at presentation | |||||
| Fever | 149 (75.3) | 12 (75.0) | 50 (78.2) | 18 (64.3) | 69 (77.5) |
| Cough | 121 (61.1) | 10 (62.5) | 45 (70.3) | 18 (64.3) | 48 (53.9) |
| Shortness of breath | 52 (26.3) | 7 (43.8) | 23 (35.9) | 7 (25) | 15 (16.9) |
| Nausea or vomiting | 47 (23.7) | 4 (25.0) | 14 (21.9) | 9 (32.1) | 20 (22.5) |
| Rhinorrhea | 43 (21.7) | 5 (31.3) | 6 (9.4) | 10 (35.7) | 22 (24.7) |
| Fatigue | 27 (13.6) | 2 (12.5) | 15 (23.4) | 3 (10.7) | 7 (7.9) |
| Diarrhea | 22 (11.1) | 3 (18.8) | 9 (14.1) | 2 (7.1) | 8 (9.0) |
| Sore throat | 20 (10.1) | 2 (12.5) | 3 (4.7) | 0 | 15 (16.9) |
| Myalgia | 20 (10.1) | 1 (6.3) | 6 (9.4) | 0 | 13 (14.6) |
| Wheezing |
13 (6.6) |
3 (18.8) |
3 (4.7) |
4 (14.3) |
3 (3.4) |
| Illness severity | |||||
| Hospitalized | 136 (68.7) | 13 (81.3) | 54 (84.4) | 18 (64.3) | 51 (57.3) |
| Admitted to ICU‡ | 43 (31.6) | 4 (30.8) | 25 (46.3) | 4 (22.2) | 10 (19.6) |
| Required mechanical ventilation‡ | 25 (18.4) | 3 (23.1) | 13 (24.1) | 1 (3.6) | 8 (15.7) |
| Died |
5 (2.5) |
0 |
2 (3.1) |
0 |
3 (3.4) |
| Age, y, mean/median (IQR)§ | 20.6/8.0 (1.9–40) | 26.8/24.0 (3–50.5) | 26.8/20.0 (2.5–50.5) | 3.5/1.2 (0.7–1.6) | 20.6/9.0 (3–29) |
| Days from symptom onset to hospital admission, mean/median (IQR)‡§ | 4.2/3.0 (2–5) | 3.6/3.0 (2–4) | 4.6/3.0 (2–6) | 3.9/3.0 (1–4) | 4.2/ 4.0 (2–5) |
| Days hospitalized, mean/median (IQR)‡§ | 6.5/4.0 (2–8) | 5.0/5.0 (3–5) | 8.4/6.5 (3–9.5) | 3.4/2.5 (2–4) | 6.3/ 4.0 (2–6) |
*Values are no. (%) except as indicated. Total HAdV also includes HAdV-E4 (1 case), which was in a nonhospitalized child (10–18 y). HAdV, human adenovirus; ICU, intensive care unit; IQR, interquartile range.
†Specimens from these HAdV-positive patients were not available for typing.
‡Among hospitalized HAdV patients.
§IQR = 25% and 75% quartiles.
Page created: May 16, 2016
Page updated: May 16, 2016
Page reviewed: May 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.